January 4, 2017 / 12:40 PM / 8 months ago

BRIEF-Kura oncology receives FDA clearance to proceed with clinical trial for KO-947

Jan 4 (Reuters) - Kura Oncology Inc

* Kura oncology receives FDA clearance to proceed with clinical trial for erk inhibitor ko-947 and nominates ko-539 as development candidate for menin-mll inhibitor program

* Kura Oncology Inc- company's goal for its menin-mll inhibitor program is to initiate a phase 1 clinical trial in 2018

* Kura expects to initiate a phase 1 trial of ko-947 in first half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below